Infectious Diseases News and Research

RSS

Ebola virus disease poses new challenges for healthcare professionals

The outbreak of Ebola virus disease that has claimed more than 1,000 lives in West Africa this year poses a serious, ongoing threat to that region: the spread to capital cities and Nigeria-Africa's most populous nation-presents new challenges for healthcare professionals.

15 Aug 2014

Food allergies more common in young inner-city children

Already known for their higher-than-usual risk of asthma and environmental allergies, young inner-city children appear to suffer disproportionately from food allergies as well, according to results of a study led by scientists at the Johns Hopkins Children’s Center.

15 Aug 2014

Ebola virus defeats attempts by interferon to block viral reproduction in infected cells

One of the human body's first responses to a viral infection is to make and release signaling proteins called interferons, which amplify the immune system response to viruses.

14 Aug 2014

Scientists identify gene that regulates sleep and wake rhythms

Scientists at the Salk Institute for Biological Studies have identified a gene that regulates sleep and wake rhythms.

14 Aug 2014

Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Microbiologist Karl Klose, a professor in the UTSA College of Sciences' Department of Biology and a member of the South Texas Center for Emerging Infectious Diseases, has received a contract from the U.S. Department of Defense (DOD) to conduct research that would bring scholars one step closer to developing a vaccine against tularemia.

14 Aug 2014

Researchers discover new clue to understanding how TB medication attacks dormant TB bacteria

Researchers at the Johns Hopkins Bloomberg School of Public Health say they have discovered a new clue to understanding how the most important medication for tuberculosis (TB) works to attack dormant TB bacteria in order to shorten treatment.

13 Aug 2014

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the, breast, prostate, colon, ovary and lung, that have relapsed after initial salvage therapy.

13 Aug 2014

MRSA and antibiotic resistance is a major health threat

Antibiotic resistance continues at an alarming rate with the indiscriminate overuse of antibiotics given to humans and animals.

13 Aug 2014

Findings may lead to better ways for preventing gum disease, diabetes and Crohn's disease

Bacteria inside your mouth drastically change how they act when you're diseased, according to research using supercomputers at the Texas Advanced Computing Center.

13 Aug 2014

Prevalence of bacterial meningitis drops in the United States

Advances in the prevention and treatment of an often fatal condition called bacterial meningitis appear to be paying dividends in the United States, report infectious disease experts at The University of Texas Health Science Center at Houston (UTHealth) in the journal The Lancet Infectious Diseases.

13 Aug 2014

Canadian government to donate experimental vaccine to combat Ebola virus

The Honourable Rona Ambrose, Minister of Health, today announced that the Government of Canada will donate doses of an experimental Ebola vaccine developed by the Public Health Agency of Canada to the World Health Organization (WHO) in its role as an international coordinating body in responding to the ongoing Ebola outbreak in West Africa.

13 Aug 2014

Installing alcohol-based hand sanitizers in classrooms does not reduce school absences in kids

Installing alcohol-based hand sanitizer dispensers in the classrooms does not lead to reductions in the rate of school absences in children, according to a study published in this week's PLOS Medicine led by Patricia Priest and colleagues from the University of Otago, New Zealand.

13 Aug 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C.

12 Aug 2014

Bacteria may depend more on gastrointestinal age than on environmental factors in babies

Scientists believe babies are born with digestive systems containing few or no bacteria. Their guts then quickly become colonized by microbes — good and bad — as they nurse or take bottles, receive medication and even as they are passed from one adoring relative to another.

12 Aug 2014

Injecting vaccine-like compound into mice effective in protecting from malaria

A study led by Johns Hopkins Bloomberg School of Public Health researchers found that injecting a vaccine-like compound into mice was effective in protecting them from malaria.

12 Aug 2014

Mucosal lymphoid cells key to S. pneumoniae defence

Type 3 innate lymphoid cells in the lung mucosa are activated early in the course of infection with Streptococcus pneumoniae and are a major source of interleukin-22 production, research reveals.

11 Aug 2014

TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS Pharmaceuticals, Inc. today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. of Atlanta, GA.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.

7 Aug 2014

Discovery lays groundwork for new class of antibiotics for Staphylococcus aureus infections

St. Jude Children's Research Hospital scientists have discovered an enzyme that regulates production of the toxins that contribute to potentially life-threatening Staphylococcus aureus infections. The study recently appeared in the scientific journal the Proceedings of the National Academy of Sciences.

7 Aug 2014

Infectious Diseases News and Research

Ebola virus disease poses new challenges for healthcare professionals

Food allergies more common in young inner-city children

Ebola virus defeats attempts by interferon to block viral reproduction in infected cells

Scientists identify gene that regulates sleep and wake rhythms

Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Researchers discover new clue to understanding how TB medication attacks dormant TB bacteria

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MRSA and antibiotic resistance is a major health threat

Findings may lead to better ways for preventing gum disease, diabetes and Crohn's disease

Prevalence of bacterial meningitis drops in the United States

Canadian government to donate experimental vaccine to combat Ebola virus

Installing alcohol-based hand sanitizers in classrooms does not reduce school absences in kids

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Bacteria may depend more on gastrointestinal age than on environmental factors in babies

Injecting vaccine-like compound into mice effective in protecting from malaria

Mucosal lymphoid cells key to S. pneumoniae defence

TAXIS acquires novel antimicrobial drug candidates from Biota

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Discovery lays groundwork for new class of antibiotics for Staphylococcus aureus infections

Industry Focus eBook - Infectious Diseases (3rd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News